Findings

What do systematic reviews say?

3,092 questions · 3,199 findings · 339 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 714 · 22.3%GRADE not reported 181 · 5.7%Very low 695 · 21.7%Low 908 · 28.4%Moderate 568 · 17.8%High 133 · 4.2%

Oral iron vs inactive control

Blood transfusion · patients with anaemia

It is very uncertain whether oral iron changes proportion requiring blood transfusion compared with inactive control (very low certainty).

1 finding from 1 review

Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
RR 0.74 [0.55, 0.99]
3 studies · 546 participants
Very low

Oral iron vs inactive control

Length of hospital stay · patients with anaemia

1 finding from 1 review

Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 300 participants
Very low

Oral iron vs inactive control

Haemoglobin (g/dL) · patients with anaemia

1 finding from 1 review

Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 402 participants
Very low

Oral iron vs inactive control

Quality of life · patients with anaemia

1 finding from 1 review

Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 276 participants
Very low

Oral iron vs inactive control

Serious adverse events · patients with anaemia

It is very uncertain whether oral iron changes serious adverse events compared with inactive control (very low certainty).

1 finding from 1 review

Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
RR 0.96 [0.76, 1.22]
5 studies · 731 participants
Very low

IV or oral iron alone vs no treatment

Red blood cell transfusions (Subnet based on 69 studies including 18,684 participants) · patients at any age with solid cancer or haematological malignancy

IV or oral iron alone showed no clear difference in red blood cell transfusions (Subnet based on 69 studies including… compared with no treatment (low certainty).

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
RR 0.74 [0.43, 1.28]
Studies not reported
Low

IV or oral iron alone vs no treatment

Overall mortality4 (Subnet based on 71 studies including 21,576 participants) · patients at any age with solid cancer or haematological malignancy

IV or oral iron alone showed no clear difference in overall mortality4 (Subnet based on 71 studies including 21,576… compared with no treatment (low certainty).

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
RR 1.5 [0.63, 3.56]
Studies not reported
Low

IV or oral iron alone vs no treatment

Thromboembolic events · patients at any age with solid cancer or haematological malignancy

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IV or oral iron alone vs no treatment

Thrombocytopenia or haemorrhage5 (Subnet based on 13 studies including 2744 participants) · patients at any age with solid cancer or haematological malignancy

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IV or oral iron alone vs no treatment

Hypertension5 (Subnet based on 24 studies including 8383 participants) · patients at any age with solid cancer or haematological malignancy

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IV or oral iron alone vs no treatment

On‐study mortality3 (Subnet based on 55 studies including 15,074 participants) · patients at any age with solid cancer or haematological malignancy

IV or oral iron alone showed no clear difference in on‐study mortality3 (Subnet based on 55 studies including 15,074… compared with no treatment (low certainty).

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
RR 2.95 [0.71, 12.34]
Studies not reported
Low

IV or oral iron alone vs no treatment

Haemoglobin response (Subnet based on 31 studies including 6985 participants) · patients at any age with solid cancer or haematological malignancy

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings for resveratrol plus oral anti‐diabetic drugs vs placebo plus oral anti‐diabetic drugs

Diabetes complications

The review found no eligible studies for this question.

1 finding from 1 review

Resveratrol for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings for resveratrol plus oral anti‐diabetic drugs vs placebo plus oral anti‐diabetic drugs

All‐cause mortality

1 finding from 1 review

Resveratrol for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 50 participants
Very low

Summary of findings for resveratrol plus oral anti‐diabetic drugs vs placebo plus oral anti‐diabetic drugs

Diabetes‐related mortality

1 finding from 1 review

Resveratrol for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 50 participants
Very low

Summary of findings for resveratrol plus oral anti‐diabetic drugs vs placebo plus oral anti‐diabetic drugs

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Resveratrol for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings for resveratrol plus oral anti‐diabetic drugs vs placebo plus oral anti‐diabetic drugs

Adverse events

1 finding from 1 review

Resveratrol for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 50 participants
Very low

Summary of findings for resveratrol plus oral anti‐diabetic drugs vs placebo plus oral anti‐diabetic drugs

HbA1c (%)

1 finding from 1 review

Resveratrol for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 31 participants
Very low

Summary of findings for resveratrol plus oral anti‐diabetic drugs vs placebo plus oral anti‐diabetic drugs

Socioeconomic effects

The review found no eligible studies for this question.

1 finding from 1 review

Resveratrol for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Combination of manual therapy, exercise, electrotherapy and oral NSAID vs oral NSAID

Participant‐reported pain relief of 30% or greater · patients with adhesive capsulitis (frozen shoulder)

The review found no eligible studies for this question.

1 finding from 1 review

Manual therapy and exercise for adhesive capsulitis (frozen shoulder) 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found